Cargando…

Use of microspheres in embolization for unruptured renal angiomyolipomas

PURPOSE: To describe our initial experience with use of microspheres in transcatheter arterial embolization (TAE) for unruptured sporadic renal angiomyolipomas (AMLs). MATERIALS AND METHODS: Seven consecutive patients with seven unruptured sporadic renal AMLs, 6 females and 1 male, with a median age...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimohira, Masashi, Nagai, Keiichi, Ohta, Kengo, Sawada, Yusuke, Naiki, Taku, Nagai, Takashi, Yasui, Takahiro, Shibamoto, Yuta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060982/
https://www.ncbi.nlm.nih.gov/pubmed/33977148
http://dx.doi.org/10.1515/med-2021-0280
_version_ 1783681472946765824
author Shimohira, Masashi
Nagai, Keiichi
Ohta, Kengo
Sawada, Yusuke
Naiki, Taku
Nagai, Takashi
Yasui, Takahiro
Shibamoto, Yuta
author_facet Shimohira, Masashi
Nagai, Keiichi
Ohta, Kengo
Sawada, Yusuke
Naiki, Taku
Nagai, Takashi
Yasui, Takahiro
Shibamoto, Yuta
author_sort Shimohira, Masashi
collection PubMed
description PURPOSE: To describe our initial experience with use of microspheres in transcatheter arterial embolization (TAE) for unruptured sporadic renal angiomyolipomas (AMLs). MATERIALS AND METHODS: Seven consecutive patients with seven unruptured sporadic renal AMLs, 6 females and 1 male, with a median age of 45 years (range, 30–69 years), underwent TAE using microspheres between November 2016 and February 2020. We evaluated the technical success rate, complications related to the procedure, clinical success rate, and the shrinkage rate of renal AML. Technical success was defined as the completion of TAE. Clinical success was defined as presence of shrinkage of the renal AML after TAE. RESULTS: In all patients, TAE using microspheres was accomplished and technical success rate was 100% (7/7). Three patients exhibited slight pain, but it improved with only observation, and the minor complication rate was 43% (3/7) and major complication rate was 0% (0/7). After the TAE, shrinkage of renal AML was confirmed in 6 of 7 patients, and clinical success rate was 86% (6/7). The median of shrinkage rate was 47% (range, 26–83%) with a median follow-up period of 19 months (range, 4–30 months). CONCLUSION: TAE using microspheres appears to be effective and safe for unruptured sporadic renal AMLs.
format Online
Article
Text
id pubmed-8060982
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-80609822021-05-10 Use of microspheres in embolization for unruptured renal angiomyolipomas Shimohira, Masashi Nagai, Keiichi Ohta, Kengo Sawada, Yusuke Naiki, Taku Nagai, Takashi Yasui, Takahiro Shibamoto, Yuta Open Med (Wars) Communication PURPOSE: To describe our initial experience with use of microspheres in transcatheter arterial embolization (TAE) for unruptured sporadic renal angiomyolipomas (AMLs). MATERIALS AND METHODS: Seven consecutive patients with seven unruptured sporadic renal AMLs, 6 females and 1 male, with a median age of 45 years (range, 30–69 years), underwent TAE using microspheres between November 2016 and February 2020. We evaluated the technical success rate, complications related to the procedure, clinical success rate, and the shrinkage rate of renal AML. Technical success was defined as the completion of TAE. Clinical success was defined as presence of shrinkage of the renal AML after TAE. RESULTS: In all patients, TAE using microspheres was accomplished and technical success rate was 100% (7/7). Three patients exhibited slight pain, but it improved with only observation, and the minor complication rate was 43% (3/7) and major complication rate was 0% (0/7). After the TAE, shrinkage of renal AML was confirmed in 6 of 7 patients, and clinical success rate was 86% (6/7). The median of shrinkage rate was 47% (range, 26–83%) with a median follow-up period of 19 months (range, 4–30 months). CONCLUSION: TAE using microspheres appears to be effective and safe for unruptured sporadic renal AMLs. De Gruyter 2021-04-20 /pmc/articles/PMC8060982/ /pubmed/33977148 http://dx.doi.org/10.1515/med-2021-0280 Text en © 2021 Masashi Shimohira et al., published by De Gruyter https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Communication
Shimohira, Masashi
Nagai, Keiichi
Ohta, Kengo
Sawada, Yusuke
Naiki, Taku
Nagai, Takashi
Yasui, Takahiro
Shibamoto, Yuta
Use of microspheres in embolization for unruptured renal angiomyolipomas
title Use of microspheres in embolization for unruptured renal angiomyolipomas
title_full Use of microspheres in embolization for unruptured renal angiomyolipomas
title_fullStr Use of microspheres in embolization for unruptured renal angiomyolipomas
title_full_unstemmed Use of microspheres in embolization for unruptured renal angiomyolipomas
title_short Use of microspheres in embolization for unruptured renal angiomyolipomas
title_sort use of microspheres in embolization for unruptured renal angiomyolipomas
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060982/
https://www.ncbi.nlm.nih.gov/pubmed/33977148
http://dx.doi.org/10.1515/med-2021-0280
work_keys_str_mv AT shimohiramasashi useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas
AT nagaikeiichi useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas
AT ohtakengo useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas
AT sawadayusuke useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas
AT naikitaku useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas
AT nagaitakashi useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas
AT yasuitakahiro useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas
AT shibamotoyuta useofmicrospheresinembolizationforunrupturedrenalangiomyolipomas